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Abstract 22 
 23 
Peripheral sensitisation of nociceptors during disease has long been recognised 24 
as a leading cause of inflammatory pain. However, a growing body of data 25 
generated over the last decade has led to the increased understanding that 26 
peripheral sensitisation is also an important mechanism driving abdominal pain in 27 
highly prevalent functional bowel disorders, in particular irritable bowel syndrome 28 
(IBS). As such, the development of drugs that target pain-sensing nerves 29 
innervating the bowel, has the potential to be a successful analgesic strategy for 30 
the treatment of abdominal pain in both organic and functional gastrointestinal 31 
diseases. Despite the success of recent peripherally restricted approaches for the 32 
treatment of IBS, not all drugs that have shown efficacy in animal models of 33 
visceral pain have reduced pain end points in clinical trials of IBS patients, 34 
suggesting innate differences in the mechanisms of pain processing between 35 
rodents and humans, and in particular, how we model disease states. To address 36 
this gap in our understanding of peripheral nociception from the viscera and the 37 
body in general, several groups have developed experimental systems to study 38 
nociception in isolated human tissue and neurons; the findings of which we 39 
discuss in this review. Studies of human tissue identify a repertoire of human 40 
primary afferent subtypes comparable to rodent models including a nociceptor 41 
population, the targeting of which will shape future analgesic development efforts. 42 
Detailed mechanistic studies in human sensory neurones combined with unbiased 43 
RNA sequencing approaches have revealed fundamental differences in not only 44 
receptor/channel expression, but also peripheral pain pathways.   45 
 46 
Introduction 47 
 48 
Abdominal pain is a symptom common to organic (e.g. inflammatory bowel 49 
disease; IBD) and functional (e.g. irritable bowel syndrome; IBS) gastrointestinal 50 
(GI) diseases (60, 75). Clinically, its management is challenging with many 51 
commonly prescribed painkillers showing limited efficacy for the treatment of 52 
abdominal pain or contraindicated by GI side effects (52). Pain is a leading cause 53 
of long-term disease morbidity in gastroenterology, contributing to significant 54 
reduction in patient quality of life, and substantial socioeconomic costs due to 55 
increased healthcare seeking and lost productivity (66). The 2016 Global Burden 56 
of Disease Study identified that the prevalence of IBD has increased in the last 57 
decade with a concomitant increase in years lived with disability (32). 58 
Consequently, the development of effective visceral analgesics for the treatment of 59 
abdominal pain in GI disease remains a long-standing priority. One therapeutic 60 
approach to this problem is to block the activation of pain-sensing nerves, so-61 
called nociceptors, that  are responsible for the transduction and transmission of 62 
noxious stimuli from the gut to the central nervous system (CNS) (4, 11, 29, 68). 63 
Clinical evidence to support the utility of this approach with regard to visceral pain 64 
is growing, however not all studies have been successful. For example, peripheral 65 
blockade of visceral nociceptors using rectal administration of local anaesthetics 66 
has proven effective in ameliorating both spontaneous and stimuli-evoked (e.g. 67 
visceral hypersensitivity to intrarectal balloon distension) visceral pain associated 68 
with IBS (72, 73). Whilst, more recently, the use of peripherally restricted 69 
compounds within well phenotyped patient subgroups (e.g. linaclotide, an agonist 70 
of the guanylate cyclase C receptor, in constipation-predominant IBS (16); and 71 
eluxadoline, a 𝜇/𝜅-opioid receptor agonist and 𝛿-opioid receptor antagonist, in 72 
diarrhoea-predominant IBS (26)) has shown efficacy against pain endpoints in 73 
clinical trials. These data collectively provide evidence supporting a role of 74 
continued peripheral nociceptor input as a key driver in chronic visceral pain. 75 
However, not all approaches have been successful, most notably, the NK3 76 
receptor antagonist SR 142,801 was shown to inhibit the increase in pelvic 77 
afferent fibre activity and visceromotor response to colonic distension in rodents 78 
(30, 43), but the NK3 receptor antagonist Talnetant (SB-223412) failed to alter 79 
sensory thresholds or response intensity to colorectal distension in healthy human 80 
volunteers (40), and lacked efficacy against pain and discomfort endpoints in a 81 
multicenter Phase IIB trial of IBS patients conducted by GlaxoSmithKline 82 
(ClinicalTrials.gov ID: NCT00101985; EudraCT number: 2004-000848-24).  83 
 84 
Design and execution of clinical trials in functional bowel disorders should take into 85 
account high placebo responses, patient stratification and the variable and 86 
relapsing nature of these conditions (35, 67). Inadequate consideration of these 87 
factors has undoubtedly contributed to clinical trial failures in the past. In addition, 88 
inconsistencies in the translation of findings from animal models to clinical trials 89 
may be attributed to species differences in pain processing between rodent and 90 
humans, and a failure of disease models in rodents to fully recapitulate the 91 
complex and variable pathophysiology of human disease. In order to bridge this 92 
translational gap, a number of new experimental strategies have been applied to 93 
investigate human nociceptor function, including microneurography (63), human 94 
stem cell-derived sensory neurones (14, 74, 79) and primary cultures of excised 95 
human dorsal root ganglia (DRG) neurones (23, 71). Such techniques hold the 96 
promise of directly interrogating native human nociceptor function. However, the 97 
application of data generated by these strategies to visceral pain is constrained by 98 
the inaccessibility of visceral nerves, scarcity of viscerally-projecting sensory 99 
neurones within a given DRG (18) and differences between the molecular 100 
mechanisms of stimulus transduction in visceral and somatic nociceptors (8, 36).  101 
 102 
Bridging the gap: the use of human tissues to improve preclinical translation 103 
 104 
Resected bowel tissues 105 
 106 
One alternative method we, and others, have employed to address the challenge 107 
of conducting translational studies on visceral pain is to utilise macroscopically 108 
normal tissue obtained following pathological inspection from the margins of 109 
surgically resected human bowel (42, 51, 54, 56, 80). This is obtained from 110 
consenting patients undergoing surgery as part of their clinical treatment for GI 111 
diseases, most commonly bowel cancer. Using suction and wire electrode 112 
approaches, neuronal activity can be recorded from mesenteric nerves innervating 113 
ileum, colon or rectum and receptive fields identified and studied in flat-sheet 114 
preparations (54, 56).  Alternatively, mesenteric nerve activity can be recorded 115 
from the human appendix when cannulated as a tubular preparation, which 116 
enables luminal distension in a manner comparable to similar approaches in 117 
rodent tissue (36). Distension of the gut evokes pain and is commonly used as a 118 
painful stimulus in human experimental medicine studies, for example colorectal 119 
distension was classically utilised by Ritchie to demonstrate the presence of 120 
visceral hypersensitivity in IBS patients (61). As such, the use of distension as a 121 
stimulus in appendix tissue provides an attractive ex vivo preparation to model 122 
bowel pain. Both these two approaches (ileum, colon and rectum flat-sheet 123 
preparations, and tubular appendiceal preparations) have been successfully 124 
exploited to investigate human visceral afferent function in detail (36, 51). As such, 125 
these human tissue ex vivo preparations represent a translational bridge between 126 
animal models and human pain, particularly where pathology is the function of 127 
peripheral sensitisation. Importantly, use of human tissue bypasses species-128 
specific issues, such as receptor expression or coupling (although individual 129 
variation will still be a factor), and provides a model where the peripheral nerve 130 
terminal architecture remains intact. Specifically, the nerve endings studied are 131 
surrounded by and interact with supporting cells of the native environment, and 132 
function in the presence of endogenous mediators/signalling molecules. These are 133 
important considerations that cannot be replicated in pared-down cell-centric 134 
models, such as human DRG or human induced pluripotent stem cell (iPSC)-135 
derived sensory neuronal cultures.  136 
 137 
Significant progress has been made in the characterisation of visceral nociceptors 138 
in rodents using electrophysiological recordings of afferent activity in response to 139 
noxious mechanical (e.g. high distending pressures, tissue stretch or blunt probe 140 
of receptive fields by von Frey hair filaments) (7, 28), inflammatory (e.g. histamine, 141 
proteases, bradykinin and ATP) (41), bacterial (55) and ischaemic stimuli (48). 142 
These studies have classified colonic afferents into five major subgroups 143 
dependent on the presumptive anatomical location of their receptive field and 144 
sensitivity to mechanical stimuli: vascular, intramuscular, intraganglionic, mucosal, 145 
and mechanically insensitive ‘silent’ afferents. Additionally, the pelvic nerve 146 
innervating the distal colorectum also possesses muscular-mucosal afferents. 147 
These classifications have identified vascular afferents (i.e. those afferents that 148 
are closely associated with blood vessels in both the gut mesentery and 149 
penetrating intramurally into the gut wall) as a major form of nociceptor by which 150 
noxious stimuli are transduced (10). Vascular afferents, unlike muscular or 151 
mucosal subtypes, have activation thresholds to mechanical distension (>40 152 
mmHg) that are painful in humans, and they are also activated by algogenic 153 
chemical mediators such as capsaicin, bradykinin, and ATP. A recent study by our 154 
group using single-cell RNA sequencing of colonic sensory neurones has 155 
identified molecular markers for 7 molecularly distinct subtypes, further facilitating 156 
the investigation of those fibres responsible for transducing noxious stimuli (38). 157 
By understanding which sensory afferents are responsible for transducing pain, we 158 
can not only focus drug discovery efforts on mechanisms capable of modulating 159 
the neuronal sensitivity in these afferents, but also focus basic research 160 
specifically on how these afferents change in disease.  161 
 162 
Studies of human bowel afferents have identified, in addition to spontaneous 163 
activity, receptive fields responsive to von Frey hair probe (54, 56), light mucosal 164 
stroke (42) and circumferential stretch (42, 80) suggesting that a comparable 165 
repertoire of afferent subtypes to those found in rodents is also present in humans 166 
(Fig. 1). The experimental procedures undertaken in these studies were limited by 167 
not insignificant technical and experimental hurdles associated with making these 168 
recordings. For example, Jiang et al. and Peiris et al. report recording success 169 
rates of 15% and 48%, respectively, after obtaining tissue from consenting 170 
patients (42, 56). Secondly, not all fibres are mechanosensitive, for example, from 171 
20 successful recordings (from 45 specimens), Yu et al. only observed 8 sensitive 172 
to mechanical or chemical stimuli (80).  173 
 174 
More recently, McGuire et al. expanded greatly on these studies and fully 175 
characterised the mechanosensitivity of 46 human colonic afferent fibres from just 176 
under one hundred tissues identifying two main subtypes of afferent (51). 177 
Specifically, approximately half of the fibres recorded were sensitive to low weight 178 
(< 0.6 g) von Frey hair probing of the serosal surface, but not stretch or mucosal 179 
stroking, and were classified as serosal nociceptors following responses to 180 
bradykinin and ATP. By contrast, fibres sensitive to stretch were unresponsive to 181 
low weight von Frey hair probing of the serosal surface and algogenic chemical 182 
mediators, and were subsequently classified as muscular afferents. Although less 183 
frequent, receptive fields in the mesentery and some sensitive to mucosal stroke 184 
were also observed (37, 51). Additionally, a mechanically insensitive ‘silent’ 185 
population, which became mechanosensitive only after bradykinin application, was 186 
also identified in human bowel in agreement with the presence of such a 187 
population in rodent studies (28). The identification of silent nociceptors in human 188 
bowel tissue is extremely important, as such neurones are believed to contribute 189 
greatly to inflammatory pain and visceral hypersensitivity observed in patients (58). 190 
It seems apparent that detailed descriptions of rodent colonic afferent 191 
neuroanatomy are comparable to that observed in human tissues. This not only 192 
provides a rational criterion for identifying and studying nociceptors in human 193 
tissue, but also lends support to the translational validity of observations on 194 
peripheral pain processing in rodent tissue. 195 
 196 
In addition to mechanosensitivity, human afferents are sensitive to a diverse range 197 
of algogenic and inflammatory mediators comparable to findings in rodent tissue. 198 
Initially confirmed using an experimental inflammatory soup (consisting of 199 
bradykinin, 5-HT, histamine and prostaglandin E2) (56), the individual constituents 200 
of which have subsequently been shown to evoke action potential discharge in 201 
human tissues (e.g. histamine (51), PGE2 (51), bradykinin (51, 56, 80) and lastly, 202 
5-HT (51, 80); Fig. 1). In addition, transient receptor potential (TRP) channel 203 
agonists, capsaicin (TRPV1) (42, 51, 54, 56, 80) and AITC (TRPA1) (80); and 204 
purinergic receptor agonists, ATP (51), ADP and UTP (37) have also all been 205 
shown to excite variable proportions of human visceral afferents. Whilst the 206 
mechanosensitivity of those fibres responding to individual chemical stimuli has 207 
not been comprehensively characterised in all cases, in the examples where it 208 
has, serosal nociceptors are sensitive to inflammatory stimuli (e.g. ATP and 209 
bradykinin), but muscular afferents are not (51).  210 
 211 
The reproducibility of responses to both mechanical stimuli (such as von Frey hair 212 
probe and ramp distension of the appendix (36, 51)) and some chemical mediators 213 
(including bradykinin and ATP (51)) has enabled mechanistic interrogation of 214 
human afferent, and specifically nociceptor function, within individual specimens 215 
thus countering some of the inherent variability observed in the diverse population 216 
from which these tissues are sourced. Whilst desensitisation of responses to 217 
repeated 5-HT, histamine and experimental inflammatory soup application may 218 
limit pharmacological investigation in some signalling pathways (51, 56), critical 219 
translational studies are achievable using this approach. Indeed, data supporting 220 
the observed modulation of serosal nociceptor mechanosensitivity by TRPV4 in 221 
rodent studies (8, 17) was demonstrated by the TRPV4 antagonist HC067047 222 
inhibiting human nociceptor firing to repeated von Frey hair probing (51). 223 
Additionally, the anti-epileptic drug retigabine, which augments the function of 224 
voltage-gated potassium channels of the KV7 family, inhibits the colonic afferent 225 
response to bradykinin in mouse and human tissue (57). Furthermore, the 226 
unexpected finding that both genetic loss and pharmacological block (by PF-227 
5198007) of NaV1.7 in mice does not alter colonic afferent firing to noxious stimuli, 228 
was confirmed in human colonic afferents using ramp distension of human 229 
appendix in the presence of NaV1.7 blocked with PF-5198007 (36). These studies 230 
build confidence in the efficacy, or lack thereof, of novel visceral analgesic 231 
pharmacophores identified through pre-clinical animal studies capable of 232 
modulating nociceptor function. Importantly, human tissue studies can also be 233 
utilised to identify the mechanism of action for clinically effective compounds. For 234 
example, tegaserod (5-HT4 receptor agonist), a clinically effective treatment of 235 
abdominal pain in IBS-C patients, reduces rectal sensitivity in healthy subjects and 236 
pain scores in IBS patients (22, 53). Rodent studies suggest that this is mediated 237 
by a direct inhibition of visceral afferent firing (62). Using human bowel tissues, we 238 
were able to show an attenuation of serosal nociceptor mechanosensitivity and 239 
validate this mechanism of action (51), therefore bolstering the translatability of 240 
this approach.  241 
 242 
As well as investigating those mechanisms capable of modulating human afferent 243 
sensitivity, direct interrogation of human tissues has shed light on disease 244 
processes and the contribution of receptor-ligand interactions occurring at the 245 
peripheral terminal. For example, bradykinin-mediated excitation of human 246 
sensory nerves occurs via B2, but not B1, receptors (51). The blockade of 247 
adenosine receptors by CGS15943 and inhibition of P2X2/3,3 receptors by R04, 248 
failed to greatly attenuate afferent firing in response to ATP therefore highlighting 249 
the importance of P2Y receptors to purinergic signalling in human afferents (37, 250 
51). In single fibre studies, afferent firing in response to capsaicin was blocked by 251 
treatment with the TRPV1 antagonist ABT-102 (51). In contrary to its canonical 252 
blockade of sodium-hydrogen antiporter NHE3, such TRPV1 antagonism was 253 
recently reported to underpin the analgesic properties of Tenapanor, a novel 254 
therapy under investigation for the treatment of constipation-predominant IBS (20, 255 
46). 256 
 257 
The diversity of source tissues enables investigation of how nociceptor function is 258 
dependent upon sex, age and disease state. Whilst the vast majority of work 259 
conducted so far has been on ‘healthy’ tissues isolated away from cancer margins, 260 
differences in afferent sensitivity to noxious stimuli (e.g. bradykinin) with age have 261 
been suggested (80). Although these were not supported at the level of an 262 
individual nerve fibre in the much larger sample size study of McGuire and 263 
colleagues (51), it may be that a reduction in nociceptor innervation as opposed to 264 
function in remaining fibres accounts for age related changes in nociception. In 265 
addition to resections for cancer, human bowel tissue is available following 266 
colectomy for Crohn’s disease (predominantly ileocecal) and ulcerative colitis 267 
(predominantly rectum, descending and sigmoid colon) providing a model for 268 
chronic inflammation. Alternatively, access to appendicitis resections enables 269 
direct comparison of acute inflammatory processes with those of a chronic state. 270 
Initial retrospective analyses have suggested no significant difference in 271 
responses to noxious stimuli in chronically inflamed IBD tissues (37, 51), however 272 
more detailed studies are required to test specific hypotheses. Direct investigation 273 
of human tissues also enables the study of human-specific variants of 274 
receptors/channels; examples of such differences are discussed in more detail 275 
below. 276 
 277 
Whilst providing an economical and potentially valuable stepping stone between 278 
animal models and clinical trials, the use of resected human bowel tissues is not 279 
without its limitations. One potential caveat in these studies is the risk that hypoxic 280 
conditions may alter nociceptor function. Ideally studies should start as soon as 281 
possible after surgery, however for human GI tissues there are several lines of 282 
evidence suggesting that longer post-surgery times are sometimes acceptable. 283 
Often tissues are not available until late in the day requiring experiments to be 284 
conducted in the evening or after overnight storage at 4C in pre-oxygenated 285 
Krebs buffer. Both contractile responses and neuronally mediated responses to 286 
electrical field stimulation (EFS) in neuromuscular studies of isolated GI tissue 287 
strips (6, 9) were unaffected by short-term storage (< 24 hrs) at 4C. Studies using 288 
the more fragile mucosa tissues also suggest that overnight storage at 4C does 289 
not alter responses to 5-HT or forskolin (12). Whilst no comprehensive study of the 290 
effects of hypoxia on human primary afferent function has been conducted, 291 
researchers have sought to minimise the risk of hypoxia-mediated changes and 292 
maintain tissue health. Specifically, Jiang et al. report pinning tissues mucosa-side 293 
up to ensure good perfusion rates of the oxygenated Krebs buffer with the 294 
degradation prone mucosa (42). In post-hoc analysis of single unit responses of 295 
human visceral afferents to both mechanical and chemical (bradykinin and ATP) 296 
stimuli, no significant difference was observed between those stored overnight at 297 
4C compared to those used straight from surgery (51). Importantly, all groups 298 
report immediate extraction from surgery into pre-oxygenated Krebs buffer for 299 
transport to laboratories and gross dissection (42, 51, 54, 56, 80). Whilst the 300 
effects of cessation of blood supply on the tissues cannot be directly evaluated, 301 
providing that control studies are conducted within the same preparation or on 302 
tissue treated in a comparable fashion (e.g. entering oxygenated buffer as soon as 303 
possible), the risk of hypoxia-mediated changes significantly influencing 304 
conclusions drawn from such experiments should be ameliorated.  305 
 306 
When using human tissue, the effects of age, ethnicity and sex of the patient from 307 
which the tissue is acquired must also be monitored. Importantly, prior patient 308 
treatment (e.g. steroids and/or anti-tumor necrosis factor (TNF) antibodies) may 309 
also impact afferent signalling. The complexity of the system (with multiple cell 310 
types, signalling cascades and interactions) is both an advantage and a 311 
disadvantage. Human bowel tissues represent a powerful tool to investigate 312 
peripheral afferent sensitivity in situ, however detailed mechanistic studies are 313 
challenging to perform and risk influence from unforeseen cell-types present in the 314 
bowel. To combat this, academic (e.g. in the UK, CRACK-IT DRGNet), not for 315 
profit (e.g. in the US, National Disease Resource Interchange and in the 316 
Netherlands, the Netherlands Brain Bank) and commercial (e.g. Anabios) 317 
infrastructures have arisen recently to provide reliable access to human sensory 318 
neurones isolated from DRG and trigeminal ganglia (TG) of healthy donor patients, 319 
with the promise of aiding investigation of sensory processing in health and 320 
chronic pain. 321 
 322 
Cultured human DRG neurones 323 
 324 
Access to human DRG neurones has greatly facilitated translational research with 325 
initial studies exploiting avulsion and ganglionectomies in chronic pain patients or 326 
following removal from foetuses (2, 50). Fundamental differences in expression 327 
and function of ion channels and receptors have been identified between rodent, 328 
non-human primate and human DRG neurones. These include differing 329 
biophysical properties contributing to the excitability of DRG neurones with a 330 
greatly reduced input resistance and higher action potential threshold of human, 331 
compared to rat DRG neurones (23, 33). Once the threshold for action potential 332 
firing is reached however, human DRG neurones tend to fire more action 333 
potentials, that are wider and at a greater frequency (33). It is perhaps not 334 
surprising then that NaV channels contributing to both electrogenesis and to the 335 
regulation of resting membrane potential in human DRG neurones differ to those 336 
of rodents. Both tetrodotoxin (TTX)-resistant NaV channels NaV1.8 and NaV1.9 337 
exhibit altered biophysical characteristics, with human NaV1.8 possessing 338 
enhanced persistent and ramp currents capable of elongating the action potential 339 
and increasing firing rates (33), whilst human NaV1.9 can open in response to a 340 
weaker stimulus compared to rodent NaV1.9 (25). Of the NaV channels, NaV1.8 341 
and NaV1.9 in particular can regulate inflammatory and visceral pain pathways and 342 
have been proposed as pharmacological targets for intervention in visceral 343 
hypersensitivity (27, 39).  344 
Human nociceptors are far more promiscuous in their sensitivity to chemical 345 
stimuli than their rodent counterparts with significantly larger numbers responding 346 
to the TRPA1 agonist AITC (5, 23) and the inflammatory mediators bradykinin (5, 347 
34) and histamine (34). The contribution of multiple TRP channels to visceral 348 
hypersensitivity is well established (4) with histamine also sensitising TRPV1 in 349 
IBS (77). In contrast to both rodent and primate isoforms, human TRPA1 is 350 
sensitive to acidic pH (44), suggesting that its already diverse range of stimuli 351 
modalities (e.g. noxious cold, noxious heat, mechanical, irritants and bacterial 352 
lipopolysaccharide) may be expanded in humans. Furthermore, human DRG 353 
neurones possess differential GABA receptor pharmacology with GABA 354 
antagonists bicuculline and picrotoxin unable to block native GABA-sensitive Cl- 355 
currents (70). Lastly, purinergic signalling, an important contributing pathway to 356 
visceral mechanosensitivity (13), in human DRG neurones differs compared to 357 
rodent, with an absence of the P2X2 receptor subtype and also altered potency of 358 
P2X3 receptor antagonists (64).  359 
 360 
Beyond functional differences, an understanding of species-specific expression is 361 
vital for successful translation from model species to human. As just one example, 362 
although many others exist, mouse DRG neurones express more than 20 MAS-363 
related G-protein coupled receptors (MRGPRs), several of which are involved in 364 
pruriception and nociception, whilst human DRG neurones only possess 4 at high 365 
levels (3). Recent comprehensive RNA sequencing screens of both human and 366 
mouse DRG neurones are filling in the gaps left by other comparative studies (59).  367 
 368 
Of course, a caveat of such studies where adult DRG have been removed for 369 
medical reasons is that they may not be representative of healthy tissue. The 370 
development of robust surgical resection protocols (71) has enabled a more 371 
comprehensive characterisation of human sensory neurones isolated from healthy 372 
adult donors lacking chronic pain (typical examples of cause of death include head 373 
trauma, stroke and anoxia). Indeed, many recent studies have shed significant 374 
light on mechanisms regulating neuronal excitability in humans, with important 375 
species-specific differences identified in the biophysics of GABAA channel function 376 
(81) and both NaV channel kinetics and sensitivity to the chemotherapeutic 377 
paclitaxel, an agent that can produce chemotherapy-induced neuropathic pain (19, 378 
82). Parallel studies have also identified toll-like receptor-4 (TLR4) as an important 379 
effector of paclitaxel capable of modulating TRPV1 in human sensory neurones: 380 
the combined effects of which likely contribute to chemotherapy-induced 381 
neuropathic pain (47).  382 
 383 
Mechanisms important for regulating visceral pain have been investigated in 384 
human DRG neurones including proteinase-activated receptor (PAR) activity (24) 385 
and the analgesic properties of 𝛼-Conotoxin Vc1.1 from the marine cone snail 386 
Conus victoriae via GABAB receptors (15). Whilst clearly invaluable in providing 387 
translational validation of mechanism in native tissue, human DRG neuronal 388 
cultures do possess experimental limitations. Principally, as with protocols for 389 
isolating rodent DRG neurones, enzymatic dissociation, mechanical trituration and 390 
time in culture are likely to impact the expression and function of ion channels and 391 
receptor signalling pathways. Secondly, a limitation specific to working with human 392 
DRG neurones is that at present we have no method of isolating human neuronal 393 
populations that innervate a specific target organ, i.e. the GI tract. This point is 394 
especially pertinent considering that it is becoming increasingly apparent that 395 
neuronal populations isolated from differing spinal segmental regions and 396 
innervating different tissues possess distinct phenotypes (49, 57, 58, 65, 78). 397 
Thus, comparisons between rodent colorectal sensation mediated by pelvic 398 
afferents originating from sacral DRG and unlabelled human sensory neurones 399 
isolated from non-sacral DRG should be undertaken with care. RNA sequencing 400 
studies of both mouse (21, 45, 69) and human sensory neurones (1, 31, 49) have 401 
elucidated their transcriptomic diversity. Our recent extension of this to single-cell 402 
resolution of a population of sensory neurones in mouse targeting the colorectum 403 
provides a clearer phenotype for those cells relevant to gastrointestinal pain (38). 404 
However, until a molecular fingerprint or panel of marker genes is identified that 405 
can differentiate visceral from other neuronal subtypes, studies of human DRG 406 
neurone studies may only provide significant translational insight into basic pain 407 
mechanisms, with additional parallel strategies required to fully interrogate visceral 408 
pain physiology. 409 
 410 
Conclusions 411 
 412 
In order to harness the translational utility of human tissue to develop more 413 
effective drugs, researchers must combine methodologies to investigate both 414 
detailed cellular mechanism and visceral pain physiology (Fig. 2). Bringing to bear 415 
powerful new techniques to selectively ablate/modulate/excite specific neuronal 416 
populations using expression of tools such as optogenetics and chemogenetics 417 
will undoubtedly progress our understanding of visceral pain pathways. The 418 
establishment of adeno-associated viral (AAV) vectors capable of transducing 419 
human sensory neurones is an important contributor to harnessing such tools (76). 420 
Finally, in comparison to the isolation of human DRG, resected colonic tissues are 421 
a widely-accessible resource removed as part of routine surgical treatment and 422 
thus represent an ideal translational model in order to study, not only visceral 423 
afferent physiology, but also peripheral sensitisation in human more broadly.  424 
 425 
Figure 1 Legend 426 
Summary of human visceral afferent subtypes and signalling pathways 427 
investigated in resected human bowel tissues to date showing the specific 428 
receptor agonists, antagonists and ligands used to conduct these studies. A 429 
Human visceral afferent fibres are sensitive to a diverse range of chemical 430 
mediators, which have been used to confirm the expression of peripheral pain 431 
pathways. Arrows represent receptor activation/agonism. Blunt arrows represent 432 
receptor inhibitors/antagonism. B Mechanosensitivity to von Frey hair probe, 433 
stretch and mucosal stroke is used to classify fibres into subtypes. Serosal and 434 
mesenteric fibres (which collectively can be classed as vascular) are proportionally 435 
more sensitive to algogenic mediators (bradykinin and ATP), indicating a greater 436 
role in visceral nociception. ✔✔✔, high response frequency; ✔, low response 437 
frequency; ✖, no response; -, not tested. 5-HT, 5-hydroxytryptamine; 5-HTR, 5-HT 438 
receptors; AR, adenosine receptors; AITC, allyl isothiocyanate; ATP, adenosine-5-439 
triphosphate; ADP, adenosine-5-diphosphate; B2R, bradykinin receptor B2; EPR, 440 
prostaglandin E2 receptors; HR, histamine receptors; PGE2, prostaglandin E2; 441 
UTP, uridine triphosphate; TRPA1, transient receptor potential ankyrin 1; TRPV1, 442 
transient receptor potential vanilloid 1; TRPV4, transient receptor potential 443 
vanilloid 4. 444 
 445 
Figure 2 Legend 446 
Interrogating abdominal chronic pain using human tissues. Peripheral sensitisation 447 
of nociceptors innervating the bowel contributes to abdominal pain in organic and 448 
functional GI disorders with inflammatory mediators, and bacterial and dietary 449 
metabolites acting on a diverse range of signalling pathways and ion channels 450 
(including Transient Receptor Potential (TRP) channels). Using ex vivo 451 
electrophysiological recordings of mesenteric nerves isolated from resected 452 
human bowel tissues it has been possible to validate regulators of neuronal 453 
excitability in humans such as voltage-gated potassium channel KV7 and the 454 
metabotropic serotonin receptor 5-HT4. Such findings can be further investigated 455 
at the level of the cell body using primary cultures of human DRG and utilising 456 
patch-clamp electrophysiology and Ca2+ imaging techniques. The integration of, 457 
and access to, these two models of peripheral pain pathways can inform our 458 
understanding of clinical phenotypes including visceral hypersensitivity and 459 
chronic abdominal pain in conditions such as irritable bowel syndrome (IBS; 460 
constipation- (C) or diarrhea(D)-predominant or mixed (M); or post-infectious IBS). 461 
 462 
 463 
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Mechanosensitivity Chemosensitivity
Probe Stretch Stroke Bradykinin ATP
Vascular
Serosal nociceptor ✔✔✔ ✖ ✖ ✔✔✔ (43%) ✔✔✔ (40%)
Mesenteric ✔✔✔ (mesentery)✖ ✖ ✔✔✔ (100%) ✔✔✔ (100%)
Muscular ✖ ✔✔✔ ✖ ✖ (0%) ✔ (11%)
Muscular-Mucosal ✖ ✔✔✔ ✔ ✖ ✖
Mucosal ✔ ✖ ✔ - -
A
B
Clinical phenotype
IBS - C/D/M
PI - IBS
Visceral hypersensitivity
Electrophysiology
Ca2+ imaging
Human DRG 
primary culture
Human ex vivo
electrophysiology
Peripheral 
sensitisation Neuronal 
excitability
DRG
Bowel
Luminal contents
Inflammatory 
mediators
Microbiota
TRPs
KV7
5-HT4
